Ontology type: schema:ScholarlyArticle
2005-08
AUTHORSKim N. Chi, Stephen K. Chia, Ross Dixon, Michael J. Newman, Vince J. Wacher, Branimir Sikic, Karen A. Gelmon
ABSTRACTBACKGROUND: ONT-093 is an orally bioavailable inhibitor of P-glycoprotein (P-gp). In pre-clinical studies, ONT-093 could inhibit P-gp and reverse multidrug resistance at nM concentrations with no effect on paclitaxel pharmacokinetics. Phase I trials of ONT-093 in normal human volunteers showed no dose-limiting toxicities at serum concentrations associated with biologic activity achieved with doses ranging from 300 to 500 mg. METHODS: Phase I pharmacokinetic trial of ONT-093 in doses from 300 to 500 mg administered before and after intravenous paclitaxel doses of 150 to 175 mg/m(2) repeated every 21 days. All patients received paclitaxel alone on cycle 1. RESULTS: 18 patients were enrolled onto 4 dose levels. Toxicity of the combination included neutropenia, arthralgia, myalgia, and peripheral neuropathy. Four of 6 patients receiving 500 mg doses of ONT-093 and paclitaxel at 175 mg/m(2) (dose level 4) had higher-grade neutropenia with cycle 2, with 1 patient experiencing febrile neutropenia. Plasma pharmacokinetic parameters of paclitaxel were unchanged between cycle 1 and 2 for dose levels 1 to 3, but at dose level 4, 45-65% increases in paclitaxel AUC were observed in 4 of the 6 patients. Mean C(max) of ONT-093 was 9 microM (range 5-15 microM) which were 3- to 5-fold higher than in single agent studies of ONT-093. CONCLUSIONS: Doses of ONT-093 achieving serum concentrations associated with biological activity were well tolerated in combination with standard doses of paclitaxel. Toxicities of the combination in this schedule were mainly attributable to paclitaxel and dose-limiting toxicity was limited to febrile neutropenia. There was an apparent pharmacokinetic interaction between paclitaxel and ONT-093, possibly related in part to the excipient, Cremophor, present in the paclitaxel formulation. More... »
PAGES311-315
http://scigraph.springernature.com/pub.10.1007/s10637-005-1439-x
DOIhttp://dx.doi.org/10.1007/s10637-005-1439-x
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1042192945
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/16012790
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1115",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Pharmacology and Pharmaceutical Sciences",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "ATP Binding Cassette Transporter, Subfamily B, Member 1",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Adult",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Aged",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Alopecia",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Antineoplastic Agents",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Antineoplastic Agents, Phytogenic",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Arthralgia",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Dose-Response Relationship, Drug",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Drug Therapy, Combination",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Female",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Humans",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Imidazoles",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Male",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Middle Aged",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Neoplasms",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Neutropenia",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Paclitaxel",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Polyethylene Glycols",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "BC Cancer Agency",
"id": "https://www.grid.ac/institutes/grid.248762.d",
"name": [
"BC Cancer Agency, Vancouver, British Columbia, Canada"
],
"type": "Organization"
},
"familyName": "Chi",
"givenName": "Kim N.",
"id": "sg:person.01142252161.65",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01142252161.65"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "BC Cancer Agency",
"id": "https://www.grid.ac/institutes/grid.248762.d",
"name": [
"BC Cancer Agency, Vancouver, British Columbia, Canada"
],
"type": "Organization"
},
"familyName": "Chia",
"givenName": "Stephen K.",
"id": "sg:person.0743651364.39",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0743651364.39"
],
"type": "Person"
},
{
"affiliation": {
"name": [
"Ontogen Corporation, Solana Beach, California, USA"
],
"type": "Organization"
},
"familyName": "Dixon",
"givenName": "Ross",
"type": "Person"
},
{
"affiliation": {
"name": [
"Ontogen Corporation, Solana Beach, California, USA"
],
"type": "Organization"
},
"familyName": "Newman",
"givenName": "Michael J.",
"type": "Person"
},
{
"affiliation": {
"name": [
"Ontogen Corporation, Solana Beach, California, USA"
],
"type": "Organization"
},
"familyName": "Wacher",
"givenName": "Vince J.",
"type": "Person"
},
{
"affiliation": {
"alternateName": "Stanford University",
"id": "https://www.grid.ac/institutes/grid.168010.e",
"name": [
"Stanford University, Palo Alto, California, USA"
],
"type": "Organization"
},
"familyName": "Sikic",
"givenName": "Branimir",
"id": "sg:person.01262727277.82",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01262727277.82"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "BC Cancer Agency",
"id": "https://www.grid.ac/institutes/grid.248762.d",
"name": [
"BC Cancer Agency, Vancouver, British Columbia, Canada"
],
"type": "Organization"
},
"familyName": "Gelmon",
"givenName": "Karen A.",
"id": "sg:person.01173252503.80",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01173252503.80"
],
"type": "Person"
}
],
"citation": [
{
"id": "sg:pub.10.1007/s002800051053",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1022009924",
"https://doi.org/10.1007/s002800051053"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1177/38.9.1974900",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1031461172"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1177/38.9.1974900",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1031461172"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1093/jnci/92.3.205",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1032301848"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s002800000215",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1035156827",
"https://doi.org/10.1007/s002800000215"
],
"type": "CreativeWork"
},
{
"id": "https://app.dimensions.ai/details/publication/pub.1074652722",
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1200/jco.2001.19.12.2975",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1074835647"
],
"type": "CreativeWork"
},
{
"id": "https://app.dimensions.ai/details/publication/pub.1075014921",
"type": "CreativeWork"
},
{
"id": "https://app.dimensions.ai/details/publication/pub.1075201523",
"type": "CreativeWork"
},
{
"id": "https://app.dimensions.ai/details/publication/pub.1082375302",
"type": "CreativeWork"
},
{
"id": "https://app.dimensions.ai/details/publication/pub.1083187952",
"type": "CreativeWork"
}
],
"datePublished": "2005-08",
"datePublishedReg": "2005-08-01",
"description": "BACKGROUND: ONT-093 is an orally bioavailable inhibitor of P-glycoprotein (P-gp). In pre-clinical studies, ONT-093 could inhibit P-gp and reverse multidrug resistance at nM concentrations with no effect on paclitaxel pharmacokinetics. Phase I trials of ONT-093 in normal human volunteers showed no dose-limiting toxicities at serum concentrations associated with biologic activity achieved with doses ranging from 300 to 500 mg.\nMETHODS: Phase I pharmacokinetic trial of ONT-093 in doses from 300 to 500 mg administered before and after intravenous paclitaxel doses of 150 to 175 mg/m(2) repeated every 21 days. All patients received paclitaxel alone on cycle 1.\nRESULTS: 18 patients were enrolled onto 4 dose levels. Toxicity of the combination included neutropenia, arthralgia, myalgia, and peripheral neuropathy. Four of 6 patients receiving 500 mg doses of ONT-093 and paclitaxel at 175 mg/m(2) (dose level 4) had higher-grade neutropenia with cycle 2, with 1 patient experiencing febrile neutropenia. Plasma pharmacokinetic parameters of paclitaxel were unchanged between cycle 1 and 2 for dose levels 1 to 3, but at dose level 4, 45-65% increases in paclitaxel AUC were observed in 4 of the 6 patients. Mean C(max) of ONT-093 was 9 microM (range 5-15 microM) which were 3- to 5-fold higher than in single agent studies of ONT-093.\nCONCLUSIONS: Doses of ONT-093 achieving serum concentrations associated with biological activity were well tolerated in combination with standard doses of paclitaxel. Toxicities of the combination in this schedule were mainly attributable to paclitaxel and dose-limiting toxicity was limited to febrile neutropenia. There was an apparent pharmacokinetic interaction between paclitaxel and ONT-093, possibly related in part to the excipient, Cremophor, present in the paclitaxel formulation.",
"genre": "research_article",
"id": "sg:pub.10.1007/s10637-005-1439-x",
"inLanguage": [
"en"
],
"isAccessibleForFree": false,
"isPartOf": [
{
"id": "sg:journal.1094201",
"issn": [
"0167-6997",
"1573-0646"
],
"name": "Investigational New Drugs",
"type": "Periodical"
},
{
"issueNumber": "4",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "23"
}
],
"name": "A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancer",
"pagination": "311-315",
"productId": [
{
"name": "readcube_id",
"type": "PropertyValue",
"value": [
"c8fc80a9287137e22ad10277d50fa831a453b41cebf346383a4ecc7fa6058450"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"16012790"
]
},
{
"name": "nlm_unique_id",
"type": "PropertyValue",
"value": [
"8309330"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1007/s10637-005-1439-x"
]
},
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1042192945"
]
}
],
"sameAs": [
"https://doi.org/10.1007/s10637-005-1439-x",
"https://app.dimensions.ai/details/publication/pub.1042192945"
],
"sdDataset": "articles",
"sdDatePublished": "2019-04-11T10:53",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000351_0000000351/records_43235_00000000.jsonl",
"type": "ScholarlyArticle",
"url": "https://link.springer.com/10.1007%2Fs10637-005-1439-x"
}
]Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10637-005-1439-x'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10637-005-1439-x'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10637-005-1439-x'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10637-005-1439-x'
This table displays all metadata directly associated to this object as RDF triples.
216 TRIPLES
21 PREDICATES
57 URIs
39 LITERALS
27 BLANK NODES